VERA
Vera Therapeutics, Inc.
$36.19
+0.86%
2026-05-08
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Key Fundamentals
Forward P/E
-11.62
EPS (TTM)
$-5.54
ROE
-50.7%
Profit Margin
0.0%
Debt/Equity
12.79
Price/Book
4.26
Beta
0.95
Market Cap
$2.59B
Avg Volume (10D)
1.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$47.00
60D Low
$34.04
Avg Volume
1.2M
Latest Close
$36.19
Get breakout alerts for VERA
Sign up for Breakout Scanner to receive daily notifications when VERA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Vera Therapeutics, Inc. (VERA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors VERA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. VERA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.